Subject is an infant born to a mother who was exposed to study drug on a tanezumab clinical
study through direct maternal exposure; or is an infant born to a mother who is a partner
of a male patient who was exposed to study drug in a tanezumab clinical study prior to or
around the time of conception and/or is exposed during his partner's pregnancy.
There are no exclusion criteria for this study